Abstract

Over the past years, SARS-CoV-2 has shown a worrisome tendency for immune escape mutations. Up until now, this development has culminated in the emergence of SARS-CoV-2 ‘Omicron’ variants. Indeed, monoclonal antibody drugs which had previously been effective and thus approved for COVID-19 treatment are ineffective in neutralizing the currently circulating ‘Omicron’ virus strains. This is remarkably different for polyclonal immunoglobulin (IG) preparations that are manufactured from plasma of thousands of COVID-19 convalescent and/or vaccinated donors: In the present study, it is shown that the neutralizing potency of currently released IG lots against ‘Omicron’ is still in a range for which successful treatment of COVID-19 in hospitalized (i.e., symptomatic) immunocompromised patients has been proposed. Consequentially, for a prophylactic situation – the typical setting of immunodeficient patients receiving periodic IG infusions –, it can be anticipated that the effectiveness of current IG lots is even more promising.

Downloads

Authors

David McIntosh - UK Plasma Action, Petersfield, United Kingdom

Thierry Burnouf - UK Plasma Action, Petersfield, United Kingdom; Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan; International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan https://orcid.org/0000-0002-0507-9243

Michael Karbiener - Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria https://orcid.org/0000-0002-8064-2489

Maria R. Farcet - Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria https://orcid.org/0000-0002-2335-8609

Thomas R. Kreil - Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria https://orcid.org/0000-0001-9970-0987

  • Abstract viewed - 286 times
  • pdf downloaded - 124 times